News | June 23, 2022
Glenmark Pharmaceuticals to address USFDA’s observation
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
This is the first Agilent lab to receive the My Green Lab Certification and plans are under way to certify additional labs.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Both manufacturing facilities are based out of Benguluru, India
Subscribe To Our Newsletter & Stay Updated
